SciELO - Scientific Electronic Library Online

vol.128 número4La autoría en los manuscritos publicados en revistas biomédicasInmunosenescencia: pruebas cutáneas de hipersensibilidad retardada en adultos mayores chilenos autovalentes índice de autoresíndice de materiabúsqueda de artículos
Home Pagelista alfabética de revistas  

Servicios Personalizados




Links relacionados


Revista médica de Chile

versión impresa ISSN 0034-9887


ROLLAN R, Antonio et al. Treatment of Helicobacter pylori infection in patients with duodenal ulcer: A cost-benefit study. Rev. méd. Chile [online]. 2000, vol.128, n.4, pp.367-377. ISSN 0034-9887.

Background: Epidemiological differences suggest that treatments for H. pylori eradication should be locally validated. Aim: To perform a cost benefit study of different treatment options for H. pylori infection. Patients and methods: One hundred and sixty-seven patients with active duodenal ulcer and H. pylori infection who completed a 2-week treatment with one of the following regimens were included: famotidine plus amoxycillin plus metronidazole (FAM), omeprazole plus amoxycillin plus tinidazole (OAT) or lansoprazole plus clarithromycin plus amoxycillin in 3 (LAC1) or 2 (LAC2) daily doses. We compared efficacy, adverse effects and cost. Results: Eradication rate was 74.6, 72.9, 96.4 y 91.7% for FAM, OAT, LAC1 and LAC2 respectively (p<0.05). Direct cost ranged from US$ 50 for FAM to US$ 220 for LAC1. A decision analysis was carried out in a model including direct and indirect costs and considering retreatment with antibiotics after the first treatment failure and one-year treatment with H2-blockers in case of a second failure. FAM was selected as the most cost-effective option, with an estimated cost of about US$ 300 ± 148 per patient. However, cost associated to LAC2 was very similar (US$ 320 ± 58) and the lower standard deviation suggests less variation. Sensitivity analyses, considering reasonable fluctuation in parameters such as eradication rate, cost and follow-up period suggest that a regimen containing a proton pump inhibitor, clarithromycin and amoxycillin may be the most cost-effective treatment. Conclusions: These results should be confirmed in other settings, specially in ordinary clinical practice, far from clinical research. (Rev Méd Chile 2000; 128: 367-77)

Palabras clave : Amoxycillin; Antibiotics; combined; Clarithromycin; Cost-benefit analysis; Helicobacter pylori; Proton pump.

        · texto en Español


Creative Commons License Todo el contenido de esta revista, excepto dónde está identificado, está bajo una Licencia Creative Commons